Trials / Completed
CompletedNCT02927925
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daratumumab | Participants will receive daratumumab 16 mg/kg as intravenous infusion. |
Timeline
- Start date
- 2017-02-14
- Primary completion
- 2020-01-02
- Completion
- 2020-01-07
- First posted
- 2016-10-07
- Last updated
- 2021-01-14
- Results posted
- 2021-01-14
Locations
17 sites across 5 countries: China, Hong Kong, Singapore, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02927925. Inclusion in this directory is not an endorsement.